New bronchiectasis treatment Brensocatib: Is This Breakthrough a Game-Changer for Bronchiectasis? Brensocatib is the first licensed medicine designed specifically to target neutrophilic inflammation in non-cystic fibrosis bronchiectasis. Here is what the clinical trials, regulatory approvals and current UK access position mean for patients. DPP1 inhibition ASPEN trial Exacerbation reduction FDA and MHRA approval NHS access … Continue reading Brensocatib: Is this breakthrough a Game-Changer for Bronchiectasis?